AHIP Statement On Prescription Drug Proposals

posted by Clare Krusing

on September 22, 2015

For Immediate Release

Washington, D.C. — As leading presidential candidates propose policies to address prescription drug pricing, AHIP President and CEO Marilyn Tavenner issued the following statement on the need for market-based solutions to promote choice, competition, and affordability for consumers:

“From the start of this debate, we have made clear that the explosive growth in prices for prescription drugs will jeopardize patients’ access to affordable, innovative treatments. Over the past several months, consumers — as well as hospitals, providers, employers, and state Medicaid directors — have grown increasingly frustrated by drug costs that show no sign of slowing down.

“Consumers are looking to policymakers and leaders of both parties to advance meaningful solutions to these cost challenges. Yet recent proposals that would impose arbitrary caps on insurance coverage or force government negotiation on prescription drug prices will only add to the cost pressures facing individuals and families across the country. These provisions will not make drug prices more affordable. We strongly believe that greater transparency around drug pricing and more competition in the market are critical to support sustainable, private-sector solutions that deliver the best value for patients and the health system. We are committed to working with all policymakers to achieve those goals.”

To promote a more affordable prescription drug market for consumers, health plans support the following:

  • Encouraging alternative payment and incentive structures for new drugs and technology;
  • Shortening the exclusivity period for biologics to promote greater price competition and earlier access to lower-cost specialty drugs and biosimilars;
  • Prohibiting abuse of the patent process by drug companies;
  • Removing barriers at the state level that restrict the use of biosimilars;
  • Expanding research on treatment effectiveness; and
  • Promoting transparency on prescription drug research, development, and pricing.

For more information on these initiatives and health plans’ efforts to improve patient access to affordable medications, click here.


Providing Health Benefits for Over 200 Million Americans.

" "